Abstract
Background
Inborn errors of metabolism (IEMs) have been anecdotally reported in the literature as presenting with features of cerebral palsy (CP) or misdiagnosed as ‘atypical CP’. A significant proportion is amenable to treatment either directly targeting the underlying pathophysiology (often with improvement of symptoms) or with the potential to halt disease progression and prevent/minimize further damage.
Methods
We performed a systematic literature review to identify all reports of IEMs presenting with CP-like symptoms before 5 years of age, and selected those for which evidence for effective treatment exists.
Results
We identified 54 treatable IEMs reported to mimic CP, belonging to 13 different biochemical categories. A further 13 treatable IEMs were included, which can present with CP-like symptoms according to expert opinion, but for which no reports in the literature were identified. For 26 of these IEMs, a treatment is available that targets the primary underlying pathophysiology (e.g. neurotransmitter supplements), and for the remainder (n = 41) treatment exerts stabilizing/preventative effects (e.g. emergency regimen). The total number of treatments is 50, and evidence varies for the various treatments from Level 1b, c (n = 2); Level 2a, b, c (n = 16); Level 4 (n = 35); to Level 4–5 (n = 6); Level 5 (n = 8). Thirty-eight (57%) of the treatable IEMs mimicking CP can be identified by ready available metabolic screening tests in blood or urine, while the remaining IEMs require more specific and sometimes invasive tests.
Conclusions
Limited by the rare nature of IEMs and incomplete information in the literature, we conclude that (1) A surprisingly large number of IEMs can present with CP symptoms, as ‘CP mimics’, (2) although individually rare, a large proportion of these diseases are treatable such that neurological damage can either be reversed or prevented, (3) clinician awareness of treatable CP mimics is important for appropriate screening, diagnosis, and early intervention, and (4) systematic studies are required to elucidate the collective frequency of treatable IEMs in CP.
Electronic supplementary material
The online version of this article (doi:10.1186/s13023-014-0197-2) contains supplementary material, which is available to authorized users.
Keywords: Inherited metabolic diseases, Therapy, Diagnosis, Atypical cerebral palsy, Movement disorders
Background
Cerebral palsy (CP) is defined as a group of non-progressive disorders of movement and posture, which cause activity limitations due to disturbances that occurred in the developing fetal or infant brain [1]. CP is the most common cause of physical impairment in the pediatric population with a prevalence of 2–3 per 1000 live births [2,3]. Risk factors include prematurity, kernicterus/hyperbilirubinemia, early CNS infection, non-specific fetal or maternal infection, intra-partum asphyxia, birth trauma and intracranial hemorrhage or neonatal encephalitis [4]. However, despite advances in maternal care and obstetrical intervention in recent decades, the incidence of CP has not declined [5]. Characterization of CP is traditionally based on the predominant quality of motor impairment (spastic, dyskinetic, ataxic-hypotonic or mixed) [6], assessed on standard neurologic examination.
CP is frequently associated with cognitive, behavioral, and sensory impairments as well as epilepsy [7]. The most common morbidity, noted in approximately 40-65% of all children with CP, is intellectual developmental disability (IDD), defined by significant delay in two or more developmental domains at age less than 5 years and an intelligence quotient of ≤70 at older age. [8]. Children with co-occurring ID are at increased risk of emotional and behavioral problems [9] and other chronic health conditions requiring frequent hospitalizations [10,11] with a high burden of care and utilization of health services for individuals with CP and their families [7]. The associated medical expenditures are considerable; Kancerla et al. [12] showed that annual costs for children with CP exceed those of children without CP by $15,047 USD and in case of co-occurring ID by $26,617 USD. Treatment and ultimately prevention of CP (and IDD) therefore is essential to reduce the emotional and physical suffering of patients and families, and to reduce the immense health care costs.
Determination of the underlying cause of CP, whether due to a malformation, injury acquired during the pre-, peri-, or postnatal period, or a genetic aberration has obvious significance from the point of view of assessment of risk, counseling of families, and developing prevention and intervention strategies [13]. The implicit heterogeneity of CP poses a challenge for diagnosis and treatment [14], and the current management of CP follows a symptomatic approach (e.g., baclofen to relieve spasticity; occupational therapy to improve mobility; pain management).
However, there are reports in the literature of inborn errors of metabolism (IEMs) that present as CP mimics, many of which are in fact amenable to therapy targeting the underlying cause that can improve neurological outcomes. IEMs are a collection of rare genetic diseases that generally result from a deficiency of an intracellular component (e.g., an enzyme or transporter) of a metabolic pathway, resulting in an accumulation of a substrate or intermediate in a pathway and/or reduced ability to synthesize essential compounds. Often the central nervous system (CNS) is affected, leading to neurological disease [15]. An example is Segawa disease, also called GTPCH1-deficient dopa-responsive dystonia (GTPCH1-DRD), characterized by dystonia in childhood that is often misdiagnosed as CP e.g., [16,17]. This neurotransmitter disorder can be diagnosed by standard analysis of neurotransmitter metabolites in the cerebrospinal fluid. Individuals with GTPCH1-DRD benefit from treatment with BH4 [18], amine replacement, as well as levodopa. The majority of treated individuals shows rapid clinical improvement in both CP-related symptoms (spasticity, dystonia, general tone) and are able to lead “an entirely normal life” [16].
It is currently unknown how many such treatable CP-mimics exist, as the evidence has not been systematically reviewed. We model the current review after our Treatable Intellectual Disability Endeavor (TIDE) study, which published a list of 89 treatable IEMs that present with an IDD [19], and a diagnostic algorithm with App [20]. This algorithm has been implemented in more than 400 children with unexplained IDD as part of the TIDE-BC study at the British Columbia Children’s Hospital, in Vancouver, Canada, and treatable IEMs were identified in more than 5% [20], which serves as motivation for the work presented here.
Methods
We performed the first systematic review to compile evidence from the literature and clinical expertise of all IEMs that are known to present with CP symptoms, with a focus on those that are amenable to causal treatment. We aim to raise awareness of existence of CP mimics and formulate a diagnostic algorithm to support clinicians in the effective identification of these IEMs. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (http://www.prisma-statement.org/) [21].
Information sources
A systematic review was performed to identify all reports of inborn errors of metabolism (IEMs) presenting with CP symptoms by searching the PubMed database, checking reference lists of relevant articles and consulting with experts in the field. We considered only articles that were published in English, described findings in humans, and those where full text publication was available electronically through our institution’s subscription. No publication date restrictions were imposed and articles included in analyses were published between 1957–2014. The last search was performed October 15, 2014.
Definitions & Eligibility criteria
We included only studies describing diseases that are IEMs, which we have previously defined as “genetic disease involving a disorder of metabolism with confirmation based on the internationally accepted diagnostic test(s) for that IEM (gene mutations, enzyme deficiency, or specific biochemical marker); this term excludes endocrine disorders” [19]. To identify diseases most likely to be misdiagnosed as CP (i.e., to exclude adult-onset), we limited our inclusion to reports where CP symptoms (Table 1) present before 5 years of age in at least one reported case.
Table 1.
Search strategy to systematically review treatable IEMs that present as CP mimics
| Search strategy | # Treatable CP mimics | ||
|---|---|---|---|
| 1) PubMed search using combinations of alternative terms to describe the CP phenotype and IEMs | Definition: | Search terms: | 27 |
| Cerebral palsy | Cerebral palsy, spastic, spasticity, dystonia, dyskinesia, ataxia, movement disorder, gait abnormalities, hypoxic(+/−ischemic) encephalopathy, perinatal asphyxia | ||
| Inborn error of metabolism | Inborn error of metabolism, metabolic disease, amino acids, creatine, mitochondria, neurotransmitter, organic acid, urea cycle, vitamins | ||
| 2) Manual search | Reference lists of articles identified through PubMed search were manually screened for additional citations. | 15 | |
| 3) Targeted search of known treatable IEMs causing ID | Diseases listed in the TIDE App (www.treatable-id.org) as treatable IEMs searched in combination with the above IEM search terms. | 12 | |
| Total number of IEMs identified | 54 | ||
The goal of this systematic review was to identify all treatable IEMs that present with CP symptoms, rather than to identify every report. We selected the most reliable or comprehensive reference for this publication; this implies that additional case reports of CP symptoms for a given IEM beyond those cited here may exist.
Search strategy
The search strategy is outlined in Table 1. Primarily, combinations of search terms that describe cerebral palsy symptoms and inborn errors of metabolism were used to identify relevant articles in the PubMed database (see Table 1). Different combinations yielded common articles, indicating our approach is conservative and our search terms are effective. Results from all key word combination searches were pooled and sorted to identify 472 unique articles (i.e., without duplicate results), which were then manually screened based on inclusion/exclusion criteria by the first author (ELL), with duplicate publications and those that did not meet eligibility criteria being removed. As well, reference lists of these publications were screened for additional relevant articles and these were judged for inclusion using the same criteria. Finally, to ensure that we have identified all salient IEMs, we performed another search using known treatable IEMs listed in a previous publication of treatable IEMs that present with intellectual disability (ID) [19] in combination with our search terms describing CP. Initial searches were performed independently by ELL following review protocol and all possible studies were compiled into a table. The generated list of IEMs was reviewed periodically by experts SS and CvK to confirm data, refine the search strategy and inclusion criteria.
Data collection
The following information was extracted from each article: disease name, cerebral palsy symptoms as reported by the original authors, age of symptom onset, any treatment used (with the dose and frequency) and the treatment outcome as described by the authors. For completeness, we later assigned each disease to a biochemical category and retrieved OMIM identifiers, underlying genes and pattern of inheritance, appropriate diagnostic test, and standard of care treatment; all were agreed upon by expert clinicians. Diagnostic tests were compared with a recent diagnostic algorithm of treatable IEMs [20] and with accepted clinical practices (e.g., GeneReviews®). Given the positive experience with the 2-tiered protocol for the work-up the child with IDD for treatable IEMs, we have used this as a basis for the evaluation of the child with CP for similar conditions.
Characterizing treatment & effects
As most reviewed studies were case reports, the type of outcome measures varied. We noted whether or not treatment was implemented and the original author’s observations on treatment effect. However, due to the time span of the reviewed publications, some treatments are now available that were not at the time of the original publication. Therefore, we took a more objective approach of employing clinical expertise to determine the standard of care treatment for the systematically identified CP mimics and categorized them as treatable versus non-treatable. Causal treatment for this proportion of conditions has been thoroughly evaluated by us already [19], and we apply the same treatment recommendations here. For conditions where treatment was not previously reviewed by us, we adhered to guidelines for the specific IEMs and where needed provided expert input, with consideration for treatments applied in the original case reports of CP mimics.
Treatment of IEMs can be either ‘primary treatment’, which targets the pathophysiology at a cellular level and improves at least the CP features (muscle tone, rigidity, etc.) plus/minus the cognitive, behavioural, and MRI features; or ‘stabilizing/preventative treatment’, which halts decline and/or prevents further damage, especially during metabolic crises. For example, creatine supplementation in creatine deficiencies targets the underlying cause of the IEM and can reverse the features. Several disorders caused by deficiencies in vitamins or co-factors can show improvement in primary features with appropriate supplementation. Examples of stabilizing/preventative treatment include emergency regimen for fatty acid oxidation disorders, HSCT for lysosomal disorders and dietary restriction of amino acids in hyperhomocysteinemias and amnio acid disorders.
Non-treatable IEMs are those for which treatment of the underlying cause is not available (i.e., only treatment of symptoms) or has shown to not be consistently effective. We summarize currently non-treatable IEMs in the hope that when treatment does become available, clinicians will be aware that these diseases can mimic CP and can then intervene.
Levels of evidence
Levels of evidence for treatments were evaluated based on existing level classification by the Centre of Evidence-Based Medicine (www.cebm.net): Level 1a = Systematic Review of RCTs, 1b = Individual RCT, 1c = ’All or None’ [=(prolongation of) survival with therapy]; Level 2a = Systematic Review of Cohort Studies, 2b = Individual Cohort Study, 2c = ’Outcomes Research’ [focussed on end results of therapy for chronic conditions, including functioning and quality of life]; Level 3 = Systematic Review of Case–Control Studies; Level 4 = Individual Case–Control Study or Case-series/report; Level 5 = Expert opinion without critical appraisal; based on physiology, bench research or first principles.
Expert-identified CP mimics
The authors who are expert clinicians in pediatric IEMs (CvK & SS) identified 13 additional diseases which they have designated as CP mimics in their clinical experience. For the majority of these, the pathophysiology is identical to IEMs in the same category for which literature evidence does exist; for example PSPH and PSAT deficiency which are both characterized by lack of serine in the brain similar to PGHDH deficiency (primarily treatable by serine supplements), or urea cycle defects in which hyperammonemic crises cause irreversible brain damage (which are preventable via dietary manipulation and medication), just like OTC deficiency for which CP-like features have been described. Likely such diseases have not (yet) been described to present as CP in the literature, likely due to the rare frequency and the increasing challenge of publishing case reports alone. The expert opinion approach was used, so that also for these IEMs, affected individuals might also receive the benefit of early detection and intervention.
Diagnostic algorithm
To provide guidance for the identification of treatable CP-mimics, we used the 2-tiered algorithm published by van Karnebeek et al. [19] to identify treatable IEMs in children presenting with IDD: First tier tests are generally accessible and offered by most biochemical genetics laboratories around the world with reasonable turn-around times and affordable prices (total costs $567.97 CAD), including tests in blood (lactate; ammonia; copper; ceruloplasmin; plasma total homocysteine; plasma amino-acids, and bloodspot quantitative acylcarnitine profile) and in urine (creatine metabolites; purines and pyrimidines; organic acids; oligosaccharides; and glycosaminoglycans). Each of these screening tests has the potential to specifically identify treatable IEMs, which is then often confirmed via molecular and/or enzymatic analysis. The 2nd tier requires a more directed, ‘single test per disease’ approach based on signs and symptoms. In general these tests are more invasive and more expensive.
Results
Treatable IEMs
Based on the defined inclusion/exclusion criteria, we identified 54 treatable IEMs reported to mimic CP (Table 1). These are categorized alphabetically into 13 biochemical categories (Table 2): amino acids (n = 5), cerebral glucose transport (n = 1), creatine (n = 1), fatty acid-related processes (n = 3), hyperhomocysteinemia (n = 2), lipids (n = 1), lysosomal (n = 4), metals (n = 2), mitochondrial (n = 3), neurotransmission (n = 9), organic acids (n = 12), urea cycle (n = 4) and vitamins/co-factors (n = 7). The CP symptoms for each IEM and corresponding reference are described in Additional file 1: Table S1. A further 13 treatable IEMs were identified by expert clinicians on our team (Table 3) for a total of 67 treatable CP mimics. Treatment modalities included: dietary restriction/supplement, co-factor/-enzyme, vitamin, substrate inhibition, substrate reduction, bone marrow and hematopoietic stem cell transplant, gene therapy. The majority of these treatments are accessible and affordable. The total number of different treatments is 50, and evidence varies for the various treatments from Level 1b, c (n = 2); Level 2a, b, c (n = 16); Level 4 (n = 35); to Level 4–5 (n = 6); Level 5 (n = 8). For 26 (39%) of these IEMs, a treatment is available that targets the primary underlying pathophysiology with the potential to improve CP symptoms; while for the remaining 41 (61%) IEMs, treatment is available that stabilizes disease or prevents further damage (e.g., treatment of Succinic semi-aldehyde dehydrogenase deficiency (SSADH) with Vigabatrin can stabilize symptoms [22,23]).
Table 2.
Overview of all 54 treatable IEMs presenting as CP mimics identified through systematic literature review
| Biochemical category | Disease name | OMIM# | Gene(s) | Treatment | Effect | Level of evidence | CP symptoms |
|---|---|---|---|---|---|---|---|
| Amino acids | Hartnup disease | 234500 | SLC6A19 (AR) | High protein diet | Stabilizing/preventative treatment | 4-5 | Dystonia |
| Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome | 238970 | SLC25A15 (AR) | Dietary protein restriction, ornithine supplement, sodium benzoate, phenylacetate | Stabilizing/preventative treatment | 4 | Spasticity | |
| Late onset non-ketotic hyperglycinemia | 605899 | AMT/GLDC/GCSH (AR) | Glycine restriction, +/− sodium benzoate, NMDA receptor antagonists, other neuromodulating agents | Stabilizing/preventative treatment | 4-5 | Spastic diplegia | |
| Phenylketonuria (PKU) | 261600 | PAH (AR) | Dietary phenylalanine restriction +/− amino acid supplements (BH(4) supplement) | Stabilizing/preventative treatment | 2a (4) | Spastic diplegia | |
| PHGDH deficiency (Serine deficiency) | 601815 | PHGDH (AR) | L-serine & +/−glycine supplements | Primary/targeting underlying pathophysiology | 4 | Spastic diplegia/tetraparesis | |
| Cerebral glucose transport | Blood brain-barrier glucose-transporter (GLUT1) defect | 606777 | SLC2A1 (AR) | Ketogenic diet | Primary/targeting underlying pathophysiology | 4 | Spasticity, dystonia, ataxia |
| Creatine | GAMT deficiency | 612736 | GAMT (AR) | Arginine restriction, creatine & ornithine supplements | Primary/targeting underlying pathophysiology | 4 | Movement disorder: extrapyramidal signs, athetosis, & ataxia |
| Fatty acid oxidation | Medium-chain acyl-coenzyme A dehydrogenase (MCAD) deficiency | 201450 | ACADM (AR) | Emergency regimen, L-carnitine, avoid fasting | Stabilizing/preventative treatment | 2a | CP symptoms |
| Short-chain acyl-CoA dehydrogenase (SCAD) deficiency | 201470 | ACADS (AR) | Emergency regimen, L-carnitine | Stabilizing/preventative treatment | 2c | Spastic diplegia | |
| Very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiency | 201475 | ACADVL (AR) | Avoidance of fasting, low-fat diet, Medium Chain Triglyceride oild | Stabilizing/preventative treatment | 4 | Neonatal asphyxia | |
| Hyperhomo-cysteinemia | Homocystinuria due to Cystathionine β-synthase deficiency | 236200 | CBS (AR) | Methionine restriction, +/− pyridoxine, +/− betaine | Stabilizing/preventative treatment | 2c | Dystonia |
| MTHFR deficiency | 236250 | MTHFR (AR) | Betaine supplements, +/− folate, carnitine, methionine supplements | Stabilizing/preventative treatment | 4 | Ataxic gait, hypotonia, extrapyramidal movements, upper motor neuron signs | |
| Lipids | Abetalipoproteinemia | 200100 | MTTP (AR) | Low long-chain fatty acid diet with fat-soluble vitamin (i.e., A, D, E, K) supplementation | Primary/targeting underlying pathophysiology | 4 | Ataxia, abnormal gait |
| Lysosomal | Fucosidosis | 230000 | FUCA1 (AR) | Haematopoietic stem cell transplant | Stabilizing/preventative treatment | 5 | Severe spasticity; spastic paresis, generalized dystonia |
| Krabbe disease | 245200 | GALC (AR) | Haematopoietic stem cell transplant | Stabilizing/preventative treatment | 2c | Progressive spasticity | |
| Metachromatic leucodystrophy (MLD) | 250100 | ARSA (AR) | Haematopoietic stem cell transplant | Stabilizing/preventative treatment | 4-5 | Loss of all gross motor function measured by CP scale; ataxia | |
| Neimann-Pick, type C | 257220 | NPC1, NPC2 | Miglustat | Stabilizing/preventative treatment | 1b | Axial hypotonia, spastic diparesis, dystonic posturing of the hands | |
| Metals | Menkes Disease | 309400 | ATP7A | Copper histidine | Stabilizing/preventative treatment | 4 | Progressive spasticity, hypotonia |
| Wilson Disease | 277900 | ATP7B | Zinc & tetrathiomolybdate; oxcarbazepine | Stabilizing/preventative treatment | 1b | Neurological symptoms, dystonia | |
| Mitochondria | Coenzyme Q10 deficiency | 607426 | COQ2, APTX, PDSS1, PDSS2, CABC1, COQ9 (most AR) | CoQ supplements | Primary/targeting underlying pathophysiology | 4 | Spastic paresis; progressive ataxia and dystonia |
| MELAS | 540000 | mt.A3243G, mt.G13513A (mtDNA) | Arginine supplements | Stabilizing/preventative treatment | 4-5 | dx. CP | |
| Pyruvate dehydrogenase deficiency | 312170, 245348 | PDHA1 (X-linked recessive), DLAT (AR), PDHX (AR) | Ketogenic diet & thiamine | Primary/targeting underlying pathophysiology | 4 | Spastic quadriplegia; dystonia | |
| Neurotransmission | Aromatic-L-amino-acid decarboxylase deficiency | 608643 | DDC (AR) | MAO inhibitors, B6, anti-cholinergics, dopa agonists) | Primary/targeting underlying pathophysiology | 4 | Limb dystonia, athetoid movement |
| DHPR deficiency (biopterin deficiency) | 261630 | QDPR (AR) | BH4, diet, amine replacement, folinic acid | Primary/targeting underlying pathophysiology | 4 | Ataxia, gait disorder, peripheral spasticity | |
| Dopamine transporter deficiency syndrome | 126455 | SLC6A3 | Dopamine antagonist (Ropinirole) | Primary/targeting underlying pathophysiology | 4 | dx. CP | |
| GTPCH1-deficient dopa-responsive dystonia (aka Segawa’s disease) | 233910 | GCH1 (AR) | BH4, amine replacement | Primary/targeting underlying pathophysiology | 4 | dx. CP; spastic diplegia | |
| PTPS deficiency (biopterin deficiency) | 261640 | PTS (AR) | BH4, diet, amine replacement | Primary/targeting underlying pathophysiology | 4 | Dystonia; spastic extremities; generalized dystonia, choreoathetoid arm movements & axial hypotonia | |
| Sepiapterin reductase deficiency | 612716 | SPR (AR) | Amine replacement | Primary/targeting underlying pathophysiology | 4 | Limb spasticity, dystonic signs; “hypotonic cerebral palsy”; dystonia, axial hypotonia; misdx. CP | |
| Succinic semialdehyde dehydrogenase deficiency (SSADH) | 271980 | ALDH5A1 (AR) | Vigabatrin | Stabilizing/preventative treatment | 4 | Hypotonia, ataxia; gait clumsiness, dystonia | |
| Tyrosine hydroxylase deficiency | 605407 | TH (AR) | L-dopa substitution | Primary/targeting underlying pathophysiology | 4 | Spastic paraplegia/tetraparesis | |
| Vesicular monoamine transporter 2 (VMAT2) | 193001 | SLC18A2 | Dopamine aginist | Primary/targeting underlying pathophysiology | 4 | Dystonia | |
| Organic acids | β-Ketothiolase deficiency | 203750 | ACAT1 (AR) | Avoid fasting, emergency regimen, protein restriction | Stabilizing/preventative treatment | 5 | Ataxia, diplegia, hypotonia |
| 2-Methyl-3-hydroxybutyryl-CoA dehydrogenase (MHBD) deficiency | 300438 | HSD17B10 (X-linked) | Avoid fasting, emergency regimen, isoleucine restricted diet | Stabilizing/preventative treatment | 5 | Ataxia, dystonia, choreoathetosis, spastic di-/tetra-plegia, hypotonia | |
| 3-Methylcrotonyl-CoA carboxylase (MCC) deficiency | 210200; 210210 | MCC1/MCC2 (AR) | Dietary protein restriction; carnitine, glycine, biotin supplements; avoid fasting; emergency regimen | Stabilizing/preventative treatment | 5 | dx. CP | |
| 3-Methylglutaconic aciduria type 1 | 250950 | AUH (AR) | Carnitine supplements, avoid fasting, emergency regimen | Stabilizing/preventative treatment | 5 | dx. CP | |
| Ethylmalonic encephalopathy | 602473 | ETHE1 (AR) | N-acetylcysteine, oral metronidazol | Stabilizing/preventative treatment | 4 | CNS malformations, episodic ataxia; pyramidal tract signs | |
| Glutaric aciduria type I (GA1) aka glutaryl-CoA dehydrogenase deficiency | 231670 | GCDH (AR) | Lysine restriction, carnitine supplements | Stabilizing/preventative treatment | 2a | Generalized spasticity, dystonia with athethosis; dx. CP; dyskinesia, dystonic tetraparesis | |
| Isovaleric acidemia | 243500 | IVD (AR) | Dietary protein restriction, carnitine supplements, avoid fasting, emergency regimen | Stabilizing/preventative treatment | 2c | Hypotonia, paresis | |
| Multiple acyl-CoA-dehydrogenase deficiency (MADD) (aka Glutaric aciduria type II) | 231680 | ETFA, ETFB, ETFDH (AR) | Carnitine, riboflavin, β-hydroxybutyrate supplements; emergency regimen | Primary/targeting underlying pathophysiology | 5 | Encephalopathy | |
| Maple syrup urine disease | 248600 | DBT, BCKDHB, BCKDHA (AR) | Dietary restriction, branched amino-acids, avoid fasting, (liver transplantation) | Stabilizing/preventative treatment (liver tx = primary treatment) | 4 (4) | Spastic diplegic CP; paroxysmal dystonia; ataxia | |
| Methylmalonic acidemia (mutase deficiency) | 251000 | MUT (AR) | Dietary protein restriction, carnitine supplements, avoid fasting, emergency regimen | Stabilizing/preventative treatment | 2c | Total body dystonia | |
| Lesch-Nyhan syndrome | 300322 | HPRT1 (X-linked) | Haematopoietic stem cell transplant | Primary/targeting underlying pathophysiology | 4-5 | dx. Athetotic/dyskinetic CP; dystonia | |
| Propionic acidemia | 606054 | PCCA, PCCB (AR) | Dietary protein restriction, carnitine supplements, avoid fasting, emergency regimen | Stabilizing/preventative treatment | 2c | Dystonia, hypotonia | |
| Urea cycle | Argininemia | 207800 | ARG1 (AR) | Dietary protein restriction, arginine supplement, sodium benzoate, phenylbutyrate (Liver transplantation) | Stabilizing/preventative treatment (liver tx = primary treatment) | 2b (4) | Spastic diplegia, ataxia, dx. CP |
| Argininosuccinic aciduria | 207900 | ASL (AR) | Low protein diet, arginine-supplements, sodium benzoate, phenylbutyrate (liver transplantation) | Stabilizing/preventative treatment (liver tx = primary treatment) | 2b (4) | Cerebellar ataxia | |
| Citrullinemia, type II | 605814 | SLC25A13 (AR) | Dietary protein restriction, arginine supplement, sodium benzoate, phenylbutyrate (Liver transplantation) | Stabilizing/preventative treatment (liver tx = primary treatment) | 2b (4) | dx. CP; spastic quadriplegia | |
| Ornithine transcarbamylase deficiency | 311250 | OTC (X-linked) | Dietary protein restriction, citrulline supplements, sodium benzoate/phenylbutyrate (Liver transplantation) | Stabilizing/preventative treatment (liver tx = primary treatment) | 2b (4) | Hemiplegia; ataxia; gait disturbance | |
| Vitamins/Co-factors | Biotinidase deficiency | 2532760 | BTD (AR) | Biotin supplement | Primary/targeting underlying pathophysiology | 2c | Spastic tetraparesis |
| Biotin-thiamine-responsive basal ganglia disease | 607483 | SLC19A3 (AR) | Biotin supplement | Primary/targeting underlying pathophysiology | 4 | Ataxia, dystonia | |
| Cerebral folate deficiency syndrome | 613068 | FOLR1 (AR) | Folinic acid | Primary/targeting underlying pathophysiology | 4 | spastic paraplegia; perinatal asphyxia | |
| Holocarboxylase synthetase deficiency | 253270 | HLCS (AR) | Biotin supplement | Primary/targeting underlying pathophysiology | 4 | dx. CP | |
| Hypermanganesemia with dystonia, polycythemia, and cirrhosis (HMDPC) | 613280 | SLC30A10 (AR) | Chelation therapy | Primary/targeting underlying pathophysiology | 4 | Dystonia | |
| Molybdenum cofactor deficiency | 252150 | MOCS1, MOCS2, (AR) | Precursor Z/cPMP | Primary/targeting underlying pathophysiology | 4 | Spastic quadriplegia dx. CP | |
| Pyridoxamine 5’-phosphate oxidase deficiency | 610090 | PNPO (AR) | Pyridoxal 5’-phosphate | Stabilizing/preventative treatment | 4 | Spastic quadriplegia |
Emergency regimen is defined as: Adjustment in management of a particular IEM to prevent or minimize metabolic decompensations (and related complications) during illness, periods of decreased intake or increased energy demand. The mainstay includes high caloric intake, generous fluid management (oral, tube or intravenous), addition/increase of vitamins/co-factors or medications, along with avoidance of substances which cannot be metabolized in patients with this IEM [24].
The IEMs are grouped according to the biochemical phenotype as presented in standard textbooks, and alphabetically.
Table 3.
Overview of all 13 treatable IEMs presenting as CP mimics identified by clinical experts on our team
| Biochemical category | Disease name | OMIM# | Gene(s) | Treatment | Effect | Level of evidence |
|---|---|---|---|---|---|---|
| Amino acids | PSAT deficiency | 610992 | PSAT1 (AR) | L-serine & +/−glycine supplements | Primary/targeting underlying pathophysiology | 4 |
| PSPH deficiency (Serine deficiency) | 614023 | PSPH (AR) | L-serine & +/−glycine supplements | Primary/targeting underlying pathophysiology | 4 | |
| Creatine | Arginine:glycine amidinotransferase (AGAT) deficiency | 612718 | GATM (AR) | Creatine supplements | Primary/targeting underlying pathophysiology | 4 |
| Creatine transporter deficiency | 300352 | SLC6A8 (X-linked) | Creatine, glycine, arginine supplements | Primary/targeting underlying pathophysiology | 4 | |
| Fatty acid oxidation | Carnitine palmitoyltransferase I deficiency | 255120 | CPT1A (AR) | Low-fat, high carbohydrate diet, avoid fasting, Medium Chain Triglyceride oil | Stablizilng/preventative treatment | 4 |
| Hyperhomocystinuria | Cobalamin deficiencies (e.g., C, D, E, F, G) | 251110, 277400, 277410, 236270, 277380 | MMACHC, MMADHC, MTRR, LMBRD1, MTR (AR) | Hydroxy-/cyanocobalamin (+/− diet restriction, betaine, B12) | Stabilizing/preventative treatment | 4 |
| Lipid storage (Leukodystrophy) | Cerebrotendinous xanthomatosis (CTX) | 213700 | CYP27A1 (AR) | Chenodeoxycholic acid | Stabilizing/preventative treatment | 4 |
| Organic acids | HMG-CoA lyase deficiency | 246450 | HMGCL (AR) | Protein restriction, avoid fasting, emergency regimen | Stabilizing/preventative treatment | 4-5 |
| mHMG-CoA synthase deficiency | 605911 | HMGCS2 (AR) | Avoid fasting,emergency regimen, +/−dietary precursor restriction | Stabilizing/preventative treatment | 5 | |
| SCOT deficiency | 245050 | OXCT1 (AR) | Avoid fasting, protein restriction, emergency regimen | Stabilizing/preventative treatment | 5 | |
| Urea cycle | Carbamoyl phosphate synthetase (CPS) deficiency | 237300 | CPS1 (AR) | Dietary protein restriction, arginine supplement, sodium benzoate, phenylbutyrate (Liver transplantation) | Stabilizing/preventative treatment (primary/targeting underlying pathophysiology) | 2b (4) |
| Citrullinemia type I (ASS deficiency) | 215700 | ASS1 (AR) | Dietary protein restriction, arginine supplement, sodium benzoate, phenylbutyrate (Liver transplantation) | Stabilizing/preventative treatment (primary/targeting underlying pathophysiology) | 2b (4) | |
| N-acetyl-glutamate synthetase deficiency | 237310 | NAGS (AR) | Dietary protein restriction, arginine supplement, sodium benzoate, phenylbutyrate (Liver transplantation) | Stabilizing/preventative treatment | 4 |
The IEMs are grouped according to the biochemical phenotype as presented in standard textbooks, and alphabetically.
Thirty-eight of the 67 disorders (57%) of the treatable IEMs described in this review can be identified by ‘1st tier’ metabolic screening tests in blood or urine (Table 4). The other 29 (43%) require more specific and sometimes invasive methods (‘2nd tier tests’; Table 5). Of the 1st tier tests in the Treatable IDD protocol, urine MPS and urine oligosaccharides are not required for the diagnostic evaluation of CP for treatable IEMs. Most 1st tier tests which detect treatable IEMs described in the literature as CP mimics can also identify ‘treatable IEMs identified by expert opinion’ (e.g., urine creatine metabolites identify GAMT deficiency, but also Creatine transporter deficiency and AGAT deficiency).
Table 4.
Summary of all treatable IEMs (n = 38, 57%) that can be detected by ‘1 st -tier’ metabolic screening tests, which are affordable and accessible, with the potential to identify multiple IEMs
| Blood tests | |||
|---|---|---|---|
| Acylcarnitine profiles (n = 3) | ● MCAD deficiency | ||
| ● SCAD deficiency | |||
| ● VLCAD deficiency | |||
| Free-to-total serum/plasma carnitine (n = 1) | ● Carnitine palmitoyltransferase I deficiency | ||
| Plasma Amino Acids (n = 10) | ● Argininemia | ● Hartnup disease | ● MTHFR Deficiency (&tHcy) |
| ● Argininosuccinate lyase deficiency | ● HHH syndrome | ● Ornithine transcarbamylase deficiency | |
| ● Citrullinemia type I | ● Maple syrup urine disease | ● Phenylketonuria (PKU) | |
| ● Citrullinemia, type II | |||
| Plasma cholesterol (n = 1) | ● Cerebrotendinous xanthomatosis (CTX) | ||
| Serum copper & ceruloplasmin (n = 2) | ● Menkes Disease (& urine deoxypyridinoline) | ||
| ● Wilson Disease (& urine copper) | |||
| Urine tests | |||
| Urine creatine metabolites (n = 1) | ● GAMT deficiency | ||
| Urine oligosaccharides (n = 1) | ● Fucosidosis | ||
| Urine organic acids (n = 17) | ● 3-Methylglutaconic aciduria type 1 | ● Ethylmalonic encephalopathy (& ACP) | ● MHBD deficiency |
| ● 3-Methylcrotonyl-CoA carboxylase (MCC) deficiency (& ACP) | ● SSADH | ● HMG-CoA lyase deficiency | |
| ● β-Ketothiolase deficiency | ● Glutaric aciduria type I | ● mHMG-CoA synthase deficiency | |
| ● Cobalamin deficiencies (& PAA) | ● Holocarboxylase synthetase deficiency | ● Multiple acyl-CoA-dehydrogenase deficiency (MADD) | |
| ● Cystathionine β-synthase deficiency | ● Isovaleric academia | ● Propionic academia | |
| ● Methylmalonic academia | ● SCOT deficiency | ||
| Urine purines & pyrimidines (n = 2) | ● Lesch-Nyhan syndrome | ||
| ● Molybdenum cofactor deficiency |
Abbreviations include: ACP acylcarnitine profiles, tHcy total homocystine, PAA plasma amnio acids.
Table 5.
All IEMs (n = 29, 43%) requiring a specific ‘2 nd -tier’ test for diagnosis
| Biochemical category | Disease | Diagnostic test |
|---|---|---|
| Amino acids | PSAT deficiency | CSF amino acids (& PAA) |
| PSPH deficiency (Serine deficiency) | CSF amino acids (& PAA) | |
| Late onset non-ketotic hyperglycinemia | CSF AA (& Plasma AA) | |
| PHGDH deficiency (Serine deficiency) | CSF AA (& Plasma AA) | |
| Cerebral glucose transport | Blood brain-barrier glucose-transporter (GLUT1) defect | CSF glucose:plasma glucose ratio |
| Creatine | Arginine: glycine amidinotransferase (AGAT) deficiency | GATM gene sequencing |
| Creatine transporter deficiency | SLC6A8 gene sequencing | |
| Lipids | Abetalipoproteinemia | CBC smear, stool samples, fasting lipid profile, MTTP gene analysis |
| Lysosomal | Krabbe disease | WBC enzyme testing |
| Metachromatic leucodystrophy (MLD) | Arylsulfatase-A enzyme activity | |
| Niemann-Pick, type C | Filipin staining test (fibroblasts) & NPC1/NPC2 gene analyses | |
| Mitochondria | Coenzyme Q10 deficiency | Coenzyme Q10 (fibroblasts) & gene(s) analysis |
| MELAS | Mitochondrial DNA mutation testing | |
| Pyruvate dehydrogenase deficiency | Blood & CSF lactate:pyruvate ratio (enzyme activity, gene(s) analysis) | |
| Neurotransmission | Aromatic-L-amino-acid decarboxylase deficiency | CSF biogenic amines |
| DHPR deficiency (biopterin deficiency) | CSF neurotransmitters & biopterin loading test | |
| Dopamine transporter deficiency syndrome | CSF neurotransmitters | |
| GTPCH1-deficient dopa-responsive dystonia | CSF neurotransmitters & biopterin/Phe loading test; clinical trial of L-dopamine, GTCPH gene analysis | |
| PTPS deficiency (biopterin deficiency) | CSF neurotransmitters & biopterin loading test | |
| Sepiapterin reductase deficiency | CSF neurotransmitters & biopterin/Phe loading test | |
| Tyrosine hydroxylase deficiency | CSF neurotransmitters & TH gene analysis | |
| Vesicular monoamine transporter 2 (VMAT2) | CSF monoamine metabolites | |
| Urea cycle | Carbamoyl phosphate synthetase (CPS) deficiency | CPS gene analysis |
| N-acetyl-glutamate synthetase deficiency | NAGS gene analysis | |
| Vitamins/Co-factors | Biotinidase deficiency | Biotinidase enzyme activity |
| Biotin-thiamine-responsive basal ganglia disease | SLC19A3 gene analysis | |
| Cerebral folate deficiency syndrome | CSF tetrahydrofolate | |
| Hypermanganesemia with dystonia, polycythemia, and cirrhosis | Whole-blood manganese concentrations, SLC30A10 gene analysis | |
| Pyridoxamine 5’-phosphate oxidase deficiency | Plasma, CSF |
The IEMs are listed per biochemical category, with the specific biochemical/genetic diagnostic test per disease. Abbreviations include: CSF cerebrospinal fluid, PAA plasma amnio acids, Phe phenylalanine.
Non-treatable IEMs
There are several IEMs that can present as CP mimics that are not (yet) treatable. These include:
Disorders of amino acids (e.g., Hyperprolinemia type I); cholesterol (e.g., Mevalonic aciduria); lipids (e.g., FAHN, Pelizaeus-Merzbacher disease); lysosomal disorders, such as sphingolipidoses (e.g., GM1/2 gangliosidoses); mitochondrial diseases (e.g., Leigh’s disease, sulfite oxidase deficiency, respiratory chain deficiencies); metals (e.g., NBIA1, PLAN); organic acids (e.g., Fumarate Hydratase Deficiency); peroxisomes (e.g., NALD); and purine and pyrimidine disorders (e.g., Adenylosuccinase deficiency, Purine nucleoside phosphorylase deficiency). Some of these conditions have emerging treatments, but not an established standard of care treatment; for example, Canavan disease, [25] and Gaucher disease, type 3 [26].
Discussion
To our knowledge, this is the first comprehensive literature review to extensively review and compiled all the known cases of treatable IEMs with co-occurring CP-like symptoms (dystonia, movement disorder, basal ganglia lesions, etc. before age 5 years). A surprisingly high number of CP mimics were identified, totaling 67 treatable IEMs (54 evidence-based, 13 expert-identified) and 43 non-treatable IEMs.
Among the treatable IEMs, we made the distinction between treatments that address primary causes of CP symptoms versus more secondary causes. For conditions that are primarily treatable, treatment targets the underlying pathophysiology and is most effective. For example, the neurotransmitter defect Tyrosine hydroxylase (TH) deficiency is highly amenable to early intervention treatment with L-dopa shows dramatic improvement and reversal of symptoms [27,28]. In diseases with secondary causes of CP symptoms (e.g., MCADD, MSUD, organic academia, urea cycle deficiency), metabolic crises such as hypoglycemia or acidosis caused by the metabolic defect can lead to neurologic sequelae mimicking CP. For these disorders prevention or stabilization, via emergency regimen, medical diets, etc., is best possible outcome.
Several IEMs presenting as CP mimics can be identified with minimally invasive testing. For example in biotinidase deficiency, the lack of the biotinidase enzyme causes accumulation of organic acid metabolites leading to ketolactic acidosis and hyperammonemia which can develop CP-like neurological manifestation (e.g., seisures, hypotonia, ataxia, feeding problems, cognitive developmental delay, etc.) [29]. Diagnosis requires minimally invasive testing (blood sampling for serum enzyme activity) and many of these symptoms can be alleviated following biotin supplementation and permanent neurological deficits such as optic atrophy, hearing loss and/or IDD may be prevented if treated early [29].
Non-treatable IEMs were also reported with the hope that new treatments might become available in the future. For example, experimental treatments are currently being explored in trials for Pantothenate kinase 2-associated neurodegeneration (PKAN, also known as Hallervorden-Spatz disease), such as gene therapy, chelation with Deferiprone [30] to prevent neurodegeneration caused by brain iron accumulation.
Although 48% of the IEMs listed can be identified by newborn screening (NBS) in most Canadian provinces [31], NBS is not universally standardized; also some diseases or very mild cases are missed. Therefore, these treatable IEMs should not be excluded from a differential diagnosis and are important to look for as part of clinical investigations for CP. There are also be other non-IEM disorders that can present with CP symptoms (e.g. endocrine disorders [32]), which may be useful for the clinician to be aware.
Whole exome and genome sequencing allows for detection of new CP mimics and, along with other metabolomics approaches and enhanced neuroimaging, will facilitate research into the phenotypic spectrum and underlying pathophysiology of these disorders. In the future, screening for such conditions might be done by whole exome sequencing, with targeted analysis of the atypical CP genes, followed by biochemical confirmation for the IEMs listed here. However, it must be emphasized that clinical history and exam remain key in the interpretation of genomic data [33]. Furthermore the lumbar puncture, although invasive, should not be avoided as it allows for CSF neurotransmitter analysis, which is highly sensitive and often guides the clinician in further diagnostic and therapeutic decisions.
Despite our attempts to be as thorough as possible in this systematic review, we acknowledge the limitations of our study. Many of the IEMs listed are very rare diseases, with incidence ranging 1:10,000 (PKU) to 1:250,000 or less (GAMT deficiency), and thus, the number of publications is relatively low and evidence for treatments is sometimes sparse. As well, it can be difficult to publish case reports, which could contribute to a lack of literature evidence and preclude inclusion from our study. We have attempted to account for this by including expert clinician experience to identify IEMs that are not yet described in the literature. Despite our efforts to be as inclusive as possible when compiling the ‘expert’ list based on a working knowledge of IEMs that mimic CP (Table 3), we acknowledge that some of the potential candidates may have been omitted. Finally, neurologic symptoms are often insufficiently described in metabolic case reports, with focus often on the biochemical features of an IEM; this combined with the broad usage of the term of CP (and its different forms), the classification of an IEM phenotype as ‘CP mimic’ was challenging and depended on the authors’ expertise.
The extensive number of distinct IEMs that may mimic CP, each requiring particular diagnostic tests, places a significant information burden on clinicians. Here we have gone to extensive lengths to compile all known IEMs mimicking CP with the hope to help raise awareness and facilitate diagnostic approach with an established algorithm [19]. This is by no means meant as directive but rather, as a supportive tool to the clinician managing children with CP-like symptomatology. Symptoms which should prompt the clinician to search for an underlying IEM or other neurogenetic defect include -but not limited to- the following ‘red flags’: normal MRI findings imaging; abnormalities isolated to the globus pallidus; severe symptoms in the absence of a history of perinatal injury; a pattern of disease inheritance, or consanguinity; neurodevelopmental regression, or progressively worsening symptomatology; isolated muscular hypotonia; rigidity (as opposed to spasticity) on physician examination; paraplegia [33].
Early detection of treatable IEMs and timely intervention is of the utmost importance in order to prevent future brain insult and manifestation of CP symptoms. Additionally, the determination of the underlying cause of CP, whether treatable or not, has significance from the point of view of risk assessment, counselling for families, improved access to community services, better management of co-morbidities, and the development of prevention and intervention strategies [13]. This would not only spare suffering of individuals, but would have broader impact in terms of alleviating the economic and social burden of CP as well.
As with the TIDE approach of systematic screening [19], it is our hope that the use of this algorithm will provide more insight into frequency of IEMs amongst the CP population, and further increase our understanding of the etiology of CP. Most importantly, early diagnosis of IEMs will allow initiation of causal treatment to improve outcomes via the reduction of possibly prevention of the the physical burdens of CP.
Conclusions
We provided the first systematic review of treatable IEMs that can present with symptoms of CP. There are many single such reports in the literature, however, the collective incidence of treatable IEM mimicking CP is unknown and can be determined only by systematic or large-scale screening studies. Increasing clinician awareness might be worthwhile, as with timely diagnosis and appropriate treatment, these conditions can show improvement in the primary features, or stabilization and prevention of further neurologic sequelae and decline. The usefulness of our diagnostic algorithm remains to be determined but represents a first step towards increased recognition of potentially treatable conditions in the child with CP.
Acknowledgements
This work was performed as part of the Treatable Intellectual Disability Endeavour in British Columbia (TIDE-BC, www.tidebc.org) funded by BC Children’s Hospital as 1st Collaborative Area of Innovation. CvK is funded as a Michael Smith Foundation for Health Research Scholar. We gratefully acknowledge NeuroDevNet for input on the design of this study and their valued feedback.
Additional file
Overview of all 50 treatable IEMs presenting as CP mimics identified through systematic literature review. The IEMs are grouped according to the biochemical phenotype as presented in standard textbooks, and alphabetically.
Footnotes
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ELL participated in study design, performed literature review and data collection, drafted the manuscript and performed revisions. MS provided clinical expertise and reviewed the manuscript. KB participated in study design, manuscript drafting and revision. SS provided clinical expertise, participated in the review of the literature and reviewed the manuscript. CDMvK conceived of, designed and supervised the study, reviewed literature results, provided clinical expertise, and participated in manuscript drafting and revision. All authors have read and approved the final manuscript.
Authors’ information
ELL is a Genetic counselling student at the University of British Columbia (UBC). MS is pediatric neurologist in Montreal Children’s Hospital, with special expertise in CP and IDD who has authored several guidelines and practice parameter; he is currently the Head of Pediatrics at McGill University. KB is a Post-doctoral fellow at the University of British Columbia. SS is a pediatric neurologist with expertise in neurometabolic diseases. She is head of the Biochemical Diseases division at BC Children’s Hospital, Department of Pediatrics, UBC. She is the PI of the TIDE-BC study (www.tidebc.org). CDMvK is a Pediatrician-Biochemical Geneticist and Assistant Professor at the Department of Pediatrics, UBC. She has expertise in the diagnosis and discovery of treatable IEMs in intellectual disability and related disabilities; she is PI of the TIDEX gene discovery study at the Centre for Molecular Medicine and Therapeutics. The authors declare that they have no competing interests.
Sylvia Stockler and Clara D.M. van Karnebeek-www.tidebc.org and www.treatable-id.org.
Contributor Information
Emma L Leach, Email: emma.leach@cw.bc.ca.
Michael Shevell, Email: michael.shevell@muhc.mcgill.ca.
Kristin Bowden, Email: kristinbowden10@gmail.com.
Sylvia Stockler-Ipsiroglu, Email: sstockler@cw.bc.ca.
Clara DM van Karnebeek, Email: cvankarnebeek@cw.bc.ca.
References
- 1.Rosenbaum P, Paneth N, Leviton A, Goldstein M, Bax M, Damiano D, Dan B, Jacobsson B. A report: the definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl. 2007;109:8–14. [PubMed] [Google Scholar]
- 2.Oskoui M, Coutinho F, Dykeman J, Jetté N, Pringsheim T. An update on the prevalence of cerebral palsy: a systematic review and meta-analysis. Dev Med Child Neurol. 2013;55(6):509–519. doi: 10.1111/dmcn.12080. [DOI] [PubMed] [Google Scholar]
- 3.Kirby RS, Wingate MS, Van Naarden BK, Doernberg NS, Arneson CL, Benedict RE, Mulvihill B, Durkin MS, Fitzgerald RT, Maenner MJ, Patz JA, Yeargin-Allsopp M. Prevalence and functioning of children with cerebral palsy in four areas of the United States in 2006: a report from the Autism and Developmental Disabilities Monitoring Network. Res Dev Disabil. 2011;32(2):462–469. doi: 10.1016/j.ridd.2010.12.042. [DOI] [PubMed] [Google Scholar]
- 4.Nelson KB. The epidemiology of cerebral palsy in term infants. Ment Retard Dev Disabil Res Rev. 2002;8(3):146–150. doi: 10.1002/mrdd.10037. [DOI] [PubMed] [Google Scholar]
- 5.Stanley FJ, Blair E. Why have we failed to reduce the frequency of cerebral palsy? Med J Aust. 1991;154(9):623–626. doi: 10.5694/j.1326-5377.1991.tb121226.x. [DOI] [PubMed] [Google Scholar]
- 6.Minear WL. A classification of cerebral palsy. Pediatrics. 1956;18(5):841–852. [PubMed] [Google Scholar]
- 7.Shevell MI, Dagenais L, Hall N, REPACQ Consortium Comorbidities in cerebral palsy and their relationship to neurologic subtype and GMFCS level. Neurology. 2009;72(24):2090–2096. doi: 10.1212/WNL.0b013e3181aa537b. [DOI] [PubMed] [Google Scholar]
- 8.Pakula AT, Van Naarden BK, Yeargin-Allsopp M. Cerebral palsy: classification and epidemiology. Phys Med Rehabil Clin N Am. 2009;20(3):425–452. doi: 10.1016/j.pmr.2009.06.001. [DOI] [PubMed] [Google Scholar]
- 9.Parkes J, White-Koning M, Dickinson HO, Thyen U, Arnaud C, Beckung E, Fauconnier J, Marcelli M, McManus V, Michelsen SI, Parkinson K, Colver A. Psychological problems in children with cerebral palsy: a cross-sectional European study. J Child Psychol Psychiatry. 2008;49(4):405–413. doi: 10.1111/j.1469-7610.2007.01845.x. [DOI] [PubMed] [Google Scholar]
- 10.Dosa NP, Boeing NM, Ms N, Kanter RK. Excess risk of severe acute illness in children with chronic health conditions. Pediatrics. 2001;107(3):499–504. doi: 10.1542/peds.107.3.499. [DOI] [PubMed] [Google Scholar]
- 11.Liptak GS, Shone LP, Auinger P, Dick AW, Ryan SA, Szilagyi PG. Short-term persistence of high health care costs in a nationally representative sample of children. Pediatrics. 2006;118(4):e1001–e1009. doi: 10.1542/peds.2005-2264. [DOI] [PubMed] [Google Scholar]
- 12.Kancherla V, Amendah DD, Grosse SD, Yeargin-Allsopp M, Van Naarden BK. Medical expenditures attributable to cerebral palsy and intellectual disability among Medicaid-enrolled children. Res Dev Disabil. 2012;33(3):832–840. doi: 10.1016/j.ridd.2011.12.001. [DOI] [PubMed] [Google Scholar]
- 13.Ashwal S, Russman BS, Blasco PA, Miller G, Sandler A, Shevell M, Stevenson R, Quality Standards Subcommittee of the American Academy of Neurology: Practice Committee of the Child Neurology Society Practice parameter: diagnostic assessment of the child with cerebral palsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2004;62(6):851–863. doi: 10.1212/01.WNL.0000117981.35364.1B. [DOI] [PubMed] [Google Scholar]
- 14.Shevell M, Dagenais L, Oskoui M. The epidemiology of cerebral palsy: new perspectives from a Canadian registry. Semin Pediatr Neurol. 2013;20(2):60–64. doi: 10.1016/j.spen.2013.06.008. [DOI] [PubMed] [Google Scholar]
- 15.Saudubray JM, Desguerre I, Sedel F, Charpentier C. A clinical approach to inherited metabolic diseases. Berlin Heidelberg: Springer; 2006. Acute symptoms in the neonatal period and early infancy; pp. 6–10. [Google Scholar]
- 16.Boyd K, Patterson V. Dopa responsive dystonia: a treatable condition misdiagnosed as cerebral palsy. Br Med J. 1989;298:1019–1020. doi: 10.1136/bmj.298.6679.1019. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Nygaard TG, Waran SP, Levine RA, Naini AB, Chutorian AM. Dopa-responsive dystonia simulating cerebral palsy. Pediatr Neurol. 1994;11(3):236–240. doi: 10.1016/0887-8994(94)90109-0. [DOI] [PubMed] [Google Scholar]
- 18.Longo N. Disorders of biopterin metabolism. J Inherit Metab Dis. 2009;32(3):333–342. doi: 10.1007/s10545-009-1067-2. [DOI] [PubMed] [Google Scholar]
- 19.van Karnebeek CD, Stockler S. Treatable inborn errors of metabolism causing intellectual disability: a systematic literature review. Mol Genet Metab. 2012;105(3):368–381. doi: 10.1016/j.ymgme.2011.11.191. [DOI] [PubMed] [Google Scholar]
- 20.van Karnebeek CDM, Shevell M, Zschocke J, Moeschler JB, Stockler S. The metabolic evaluation of the child with an intellectual developmental disorder: Diagnostic algorithm for identification of treatable causes and new digital resource. Mol Genet Metab. 2014;111(4):428–438. doi: 10.1016/j.ymgme.2014.01.011. [DOI] [PubMed] [Google Scholar]
- 21.Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. doi: 10.1136/bmj.b2700. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Gibson KM, Christensen E, Jakobs C, Fowler B, Clarke MA, Hammersen G, Raab K, Kobori J, Moosa A, Vollmer B, Rossier E, Iafolla AK, Matern D, Brouwer OF, Finkelstein J, Aksu F, Weber HP, Bakkeren JA, Gabreels FJ, Bluestone D, Barron TF, Beauvais P, Rabier D, Santos C, Umansky R, Lehnert W. The clinical phenotype of succinic semialdehyde dehydrogenase deficiency (4-hydroxybutyric aciduria): case reports of 23 new patients. Pediatrics. 1997;99(4):567–574. doi: 10.1542/peds.99.4.567. [DOI] [PubMed] [Google Scholar]
- 23.Leuzzi V, Di Sabato ML, Deodato F, Rizzo C, Boenzi S, Carducci C, Malaspina P, Liberanome C, Dionisi-Vici C. Vigabatrin improves paroxysmal dystonia in succinic semialdehyde dehydrogenase deficiency. Neurology. 2007;68(16):1320–1321. doi: 10.1212/01.wnl.0000259537.54082.6d. [DOI] [PubMed] [Google Scholar]
- 24.Dixon MA, Leonard JV. Intercurrent illness in inborn errors of intermediary metabolism. Arch Dis Child. 1992;67(11):387–1391. doi: 10.1136/adc.67.11.1387. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Zano S, Malik R, Szucs S, Matalon R, Viola RE. Modification of aspartoacylase for potential use in enzyme replacement therapy for the treatment of Canavan disease. Mol Genet Metab. 2011;102(2):176–180. doi: 10.1016/j.ymgme.2010.10.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Rice EO, Mifflin TE, Sakallah S, Lee RE, Sansieri CA, Barranger JA. Gaucher disease: studies of phenotype, molecular diagnosis and treatment. Clin Genet. 1996;49:111–118. doi: 10.1111/j.1399-0004.1996.tb03268.x. [DOI] [PubMed] [Google Scholar]
- 27.Furukawa Y, Graf WD, Wong H, Shimadzu M, Kish SJ. Dopa-responsive dystonia simulating spastic paraplegia due to tyrosine hydroxylase (TH) gene mutations. Neurology. 2001;56(2):260–263. doi: 10.1212/WNL.56.2.260. [DOI] [PubMed] [Google Scholar]
- 28.Hoffmann GF, Assmann B, Bräutigam C, Dionisi-Vici C, Häussler M, de Klerk JB, Naumann M, Steenbergen-Spanjers GC, Strassburg HM, Wevers RA. Tyrosine hydroxylase deficiency causes progressive encephalopathy and dopa-nonresponsive dystonia. Ann Neurol. 2003;54(Suppl 6):S56–S65. doi: 10.1002/ana.10632. [DOI] [PubMed] [Google Scholar]
- 29.Wolf B. The neurology of biotinidase deficiency. Mol Genet Metab. 2011;104(1–2):27–34. doi: 10.1016/j.ymgme.2011.06.001. [DOI] [PubMed] [Google Scholar]
- 30.Cossu G, Abbruzzese G, Matta G, Murgia D, Melis M, Ricchi V, Galanello R, Barella S, Origa R, Balocco M, Pelosin E, Marchese R, Ruffinengo U, Forni GL. Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): results from a four years follow-up. Parkinsonism Relat Disord. 2014;20(6):651–654. doi: 10.1016/j.parkreldis.2014.03.002. [DOI] [PubMed] [Google Scholar]
- 31.Adams J: Newborn Screening in Canada Status Report. In ᅟ. ; 2012. http://www.cadth.ca/products/environmental-scanning/environmental-scans/newborn-screening.
- 32.Tonduti D, Vanderver A, Berardinelli A, Schmidt JL, Collins CD, Novara F, Genni AD, Mita A, Triulzi F, Brunstrom-Hernandez JE, Zuffardi O, Balottin U, Orcesi S. MCT8 deficiency: extrapyramidal symptoms and delayed myelination as prominent features. J Child Neurol. 2013;28(6):795–800. doi: 10.1177/0883073812450944. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Lee RW, Poretti A, Cohen JS, Levey E, Gwynn H, Johnston MV, Hoon AH, Fatemi A: A diagnostic approach for cerebral palsy in the genomic era.Neuromolecular Med ᅟ, ᅟ:. in press. [DOI] [PMC free article] [PubMed]